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There is evidence that polymorphonuclear neutrophils (PMNs) can exert severe antineoplastic eﬀects. Cross-talk between tumour
cells and endothelial cells (ECs) is necessary for the accumulation of PMN around a tumour. This work reports the ability of
two PMN-sensitive, human, permanent cell lines—colorectal adenocarcinoma (HT-29) and pharyngeal squamous-cell carcinoma
(FaDu) cells—to act as inﬂammatory foci. PMNs were cytotoxic to both lines, the adhesion of the PMNs to the tumour cells
being important in this eﬀect. The tumour cells released appreciable amounts of IL-8 and GROα, and induced the transmigration
of PMN through human microvascular-EC monolayers. Conditioning media associated with both lines induced the adhesion of
PMN and the surface expression of ICAM-1 in microvascular-EC. In addition, FaDu-conditioning-medium strongly induced the
production of proinﬂammatory cytokines by microvascular-EC. These results support the idea that tumour cells might normally
induce a potent acute inﬂammatory response, leading to their own destruction.
Copyright © 2009 Antonio Br´ u et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Polymorphonuclear neutrophils (PMNs) are the most abun-
dant circulating blood leukocytes. They play an important
role in innate immunity and provide the ﬁrst-line of defence
against infection. Additionally, there is unequivocal evidence
that PMN could play also an eﬀective antitumour role.
Edelson and Cohn reported in 1973 that lactoperoxidase
exerts a cytotoxic activity against tumour cells [1]. There-
after, Clark et al. [2] showed that peroxidase systems in
inﬂammatory cells were cytotoxic for mouse lymphoma
cells. During the next years, a number of reports appeared
describing a cytotoxic eﬀect of PMN and macrophages on
cancer cells in vitro [3–9] in animal models and in humans
[10–12]. It has been suggested that tumour progression
is associated with neutropenia or a defective capacity of
PMN to kill tumour cells [12–15]. It has been reported
also that a mouse line, genetically selected for high acute
inﬂammatory response exhibited an unusual resistance to
tumourigenesis in comparison with the line selected for
low acute inﬂammatory response. Interestingly, this mouse
line produced large amounts of PMN in bone marrow,
exhibited a high number of PMN in blood, and showed
an increased resistance of the locally inﬁltrated PMN to
spontaneously apoptose [16–19]. PMN were involved in
the antitumour action of hyperthermia in an experimental
mouse model [20]. PMN were involved also in the eﬃcacy
of the antitumour action following bacterial therapy with2 Mediators of Inﬂammation
several classes of tumours [21–24]. In 2003, a mouse
strain that was completely resistant to cancer was described
[25]. Further, it had been demonstrated that this resistance
was due to PMN, macrophages and NK cells [26]. The
mechanism of this resistance is unknown, but it seems
that the antitumour eﬀect requires the contact between the
immunecellsandthemalignantcells[27].Similarly,Jaganjac
etal.[28]showedthatPMNwereinvolvedinthewell-known
spontaneous regression of W256 carcinoma cells grown in
Sprage-Dawley rats. In addition, massive amounts of PMN
were involved also in the rejection of tumour cells that
were engineered to release the cytokines IL-2 and TNFα
[29].
It is clear that PMN play an essential role in host
defence against infection [30], but the mechanism by
which PMN causes antitumour activity is not understood
at all. It has been shown that the antitumour activity of
inﬂammatorycellsismediatedbyacombinationofoxidative
and non-oxidative mechanisms. These complex mechanisms
includeintenseproductionofreactive-oxygenspecies(ROS),
hypoclorous acid, proteases, defensins, cytostatic factors,
perforins, and membrane interactions between PMN and
target cells [6–9, 31–36].
While studying tumour growth dynamics mathemati-
cally, using fractal geometry and scaling techniques, Br´ u
et al. [37] found that growth of a solid tumour follows a
universal growth pattern known as “linear molecular beam
epitaxy.” This kind of growth dynamics is described by a
diﬀerential equation, which contains a term that accounts
for the diﬀusion of cells at the surface of the growing
cell colony. The biological interpretation of this term led
to the concept that, when a minimum of nutrients and
oxygen are maintained, tumour cells prioritizes space and
compete for it [38]. Based upon this concept, competition
of inﬂammatory cells for the space around the solid tumour
was proposed as mechanism that could contribute also to
PMN antitumour activity. To test the antitumour eﬀect of
a massive inﬁltration of PMN, a sustained treatment with
GM-CSF was applied in a mouse experimental model, and
a strong neutrophilia was achieved around the induced
tumours. Signiﬁcantly, there was 16 times lower mortality
in the treated mice than in the controls [39]. The same
therapeutic strategy was applied in a patient with advanced
hepatocarcinoma, who exhibited a complete remission after
4monthsofG-CSFtreatment[40].Thereisindirectevidence
by Su et al. [41] suggesting that the powerful antitumour
eﬀect of treatment with G-CSF is due to the up-regulation
of the PMN production in bone marrow. These authors
induced a sustained increase in the number of circulating
PMN, by means of prolonged administration of G-CSF, and
they found an unexpected survival rate in their double-
blind, placebo-controlled randomized trial for squamous
head and neck cancer. Patients in the G-CSF arm showed a
mean leukocyte count of 24100/μL during treatment period
(around 50 days) and their 5-year disease-free survival was
84%.Incomparison,thecontrolgrouphadameanleukocyte
countof4100/μLwithasurvivalrateat5yearsof47%.Other
clinical trials using continuous GM-CSF administration in
advanced prostate cancer [42] or sustained G-CSF in stage
IV melanoma with brain metastases [43]r e p o r t e dam u c h
better survival than when approved therapies were used.
Our hypothesis is that the eﬃciency of PMN against
a tumour in vivo depends chieﬂy on the ability of the
tumour to act as an inﬂammatory site to guarantee the
recruitment of cells (especially PMN) to produce a potent
acute inﬂammatory response. Recruitment of PMN from
the blood by an inﬂammatory site is a multi-step process
involving a series of coordinated interactions between PMN
and endothelial cells (EC) [44]. Some pro-inﬂammatory
mediators,suchascytokines,growthfactors,lipidmediators,
andsoforth,secretedbythecellsfromtheinﬂammatorysite,
activate EC which express adhesion molecules and elicit the
production of downstream mediators from EC. In the case
of tumours, the communication between tumour cells and
EC should be the ﬁrst step that initiates PMN accumulation
at the site of tumour. By means of diapedesis, the PMN
pass throughout the vessel wall and, to exert an antitumour
eﬀect they migrate towards the tumour cells and adhere to
them. Finally, PMN are activated to secret cytokines that
help orchestrate the antitumour immune response. Thus,
ourstudiesusingtwodiﬀerenttumourcelllinesdemonstrate
thatthetumourscanbeinﬂammatorysitesthatrecruitPMN
to which they are sensitive.
2.MaterialandMethods
2.1. Tumour Cell Lines. HT-29 and FaDu are permanent
colorectal adenocarcinoma and pharinx scamous cell carci-
noma cell lines respectively (obtained from American Type
Culture Collection-ATCC HTB-38 and ATCC HTB-43) were
grown in DMEM containing 10% foetal bovine serum (FBS)
and supplemented with 2mM L-glutamine, 1mM sodium
pyruvate, 100U/mL penicillin and 100μg/mL streptomycin
(Biological Industries, Kibutz Bet Haemek, Israel).
2.2. Isolation of PMN. PMN suspensions were obtained
as previously described [45] from heparin anticoagulated
peripheral venous blood from haematological patients suf-
fering from iron-overload and who were undergoing peri-
odic phlebotomies, following their signed consent. Cell
viability, measured by Trypan blue dye exclusion, always
exceeded 95%. Total and diﬀerential cell counts were carried
out using Sysmex XE-2100 (Roche Spain, Barcelona, Spain)
cell counter. In addition, the percentage of PMN were
assessed using staining smears. The percentage was always
higher than 95%.
2.3.IsolationandCultureofHumanMicrovascularEndothelial
Cells (HMVEC). Human dermal microvascular endothelial
cells (HMVEC) were isolated from human foreskins by
a modiﬁcation of a previously described technique [46].
Brieﬂy, foreskins were cut into 3mm2 squares and placed
in PBS containing 0.3% trypsin (Difco laboratories, Detroit,
MI) and 1% EDTA (Sigma-Aldrich Qu´ ımica S.A. Madrid,
Spain) at 37
◦C for 30 minutes. After washing the skin
fragments with PBS several times, the cells were released
by pressing into a Petri dish containing medium. TheMediators of Inﬂammation 3
microvascular segments were passed through a 150μm
nylon mesh and collected. HMVEC were cultured on
1% gelatine-coated ﬂasks in MCDB 131 supplemented
with 20% FBS, 20mM L-glutamine, 100U/mL penicillin,
100μg/mL streptomycin, 5ng/mL bFGF, 20ng/mL EGF (all
from Biological Industries) and 10U/mL heparin (Sigma).
At ﬁrst passage, HMVEC were puriﬁed with CD31-coated
Dynabeads (Invitrogen Dynal AS, Oslo, Norway) following
the manufacturer’s instructions to obtain pure cell popula-
tions of HMVEC. The microvascular endothelial cells were
identiﬁed by immunoﬂuorescence staining for vWF and
CD31. The experiments were conducted with cells that have
been cultured by 3–5 passages. Prior to the experiments, cells
were maintained for 48hours in medium containing 1% FBS
without heparin and without growth factors.
2.4. PMN Adhesion and Transendothelial Migration
Assays. PMNs were suspended in PBS at cell density of
1 ×106 PMN/mL. 1,1 -dioctadecyl-3,3,3 ,3 -tetramethyl-in-
docarbocyanine perchlorate (Dil) in ethanol was added to
yield 1μg/mL ﬁnal concentration and incubated at 37
◦Cf o r
1 hour. Afterwards, PMN were washed twice with PBS and
suspended in DMEM containing 1% FBS at the adequate cell
density. The labelled PMN suspension was warmed at 37
◦C
for 5 minutes before the assays.
The adhesion assay was performed on tumour cells
and HMVEC cultured in 12-well dishes at conﬂuence.
Cultured cells were washed twice before the addition of
0.5mL of DMEM with 1% FBS and warmed at 37
◦Cf o r
5minutes before the addition of 0.5mL of labelled PMN
suspensions containing of 2 ×106 PMN. The cells were then
incubated at 37
◦C for 30 minutes. Thereafter, the cells were
washed 4 times with PBS, and 250μLo f1 %T r i t o nX -
100 in PBS were then added. Culture dishes were shaken
for 15 minutes at room temperature and supernatant was
removed.Fluorescencewasmeasuredimmediatelyat520nm
excitation-light and 565nm emission-light. The results were
recorded as a number of PMN adhered, calculated from
a standard curve generated by measuring the ﬂuorescence
of diﬀerent known number of labelled PMN processed
identically as the adhesion samples.
For the transendothelial migration assays, tumour cells,
dermal ﬁbroblasts and HMVEC were cultured in the 12-well
tissuecultureplates.Whenthecellswereconﬂuent,theywere
washed twice with PBS and then incubated with 1mL of
DMEM, free of pH indicator (to avoid colour interference
in the ﬂuorescence measurement) containing 10% FBS, for
48 hours in a CO2 incubator. HMVEC were treated with IL-
1β for the ﬁnal 5 hours. Transendothelial migration assays
wereperformedplacingthe3μmporesizecellcultureinserts
(BD Labware Europe, Le Pont de Claix, France) in which
HMVEC were previously cultured at conﬂuence. The assay
was performed without removing conditioning media from
the wells containing tumour cells, ﬁbroblasts and IL-1β-
treated HMVEC. The medium from the inserts was removed
and 2 ×106 PMN in 500μLo f3 7
◦Cp r e - w a r m e dD M E M
free of pH indicator containing 10% FBS were then added.
The system was placed in the CO2 incubator and PMN
were allowed to cross the HMVEC monolayer for 3 hours.
After this, inserts were removed and 100μLo f1 %T r i t o n
X-100 in PBS were added to the bottom wells. Samples
were processed as described above to determine the number
of PMN that crossed. After washing integrity of HMVEC
layer was routinely controlled by microscopy observation
and no alterations were observed in any case. Non-speciﬁc
transmigration was evaluated without cells in the bottom
wells and subtracted from the values obtained with cells.
2.5. Cytotoxicity Assay. Tumour cells were cultured in 12-
well culture plates containing 12mm diameter cover glasses.
Before the assay, tumour cells were washed and 500μL
of DMEM containing 10% FBS were added. 5 × 106 PMN
suspended in 500μL of DMEM with 10% FBS were
placed in 0.4μma n d3 μm pore cell culture inserts that
were located over the wells containing the tumour cells.
Four diﬀerent conditions were assayed: PMN placed in
3μm inserts; PMN activated with 0.1μmoles/L n-formyl-
methionyl-leucyl-phenylalanine (fMLP) placed in 0.4μm
inserts; PMN placed in 3μm inserts in the presence of a
cocktail of 10μg/mL of mouse anti-human CD44 mono-
clonal antibody (ref 550990, BD Pharmingen, San Diego,
CA), 10μg/mL of mouse anti-human CD162 monoclonal
antibody (ref 556052, BD Pharmingen) and 10μg/mL of
mouse anti-human CD18 monoclonal antibody (ref 555922,
BDPharmingen)andcontrolswereperformedwithmedium
without PMN in the inserts. PMN were incubated for 30
minutes with the antibody cocktail before placing them in
the inserts. Plates containing all of the cells were incubated
for the indicated (results section) period of time in the
CO2 incubator.Coverswererecoveredformicroscopicobser-
vation after acridine orange (AO) and ethidium bromide
(EB) staining. For staining, covers were treated with a
1μg/mL AO and 5μg/mL EB solution in PBS for 15 minutes
and mounted with Fluoprep (BioM´ erieux, France) in glass
slides for microscopy, and observed in an Olympus BX50
microscope. AO permeates throughout the cells and renders
the nuclei green. EB was taken up by the cells only when
cytoplasmic membrane integrity was lost, and stained the
nuclei red.
2.6.ProteinArrayTest. Secretedcytokineswerecharacterized
with the Human Cytokines Antibody Array 3 (RayBiotech,
Inc., Norcross, GA30092, 1-888-494-8555) and samples were
processed as the protocol provided by the manufacturer.
Detection was aﬀorded by incubating 0.5mL of mixture of
the ECL Western Blotting Analysis System (GE Healthcare,
Buckinghamshire HP79NA UK) for 1 minute. X-ray ﬁlm
used was Curix RP2 and were developed with G153 devel-
oper and Rapid Fixer G354 (Agfa-Gevaert, B2640 Mortsel,
Belgium). The density of blots was measured in a GelDoc
2000 with the Quantity One software (Bio-Rad Laboratories,
Hercules, CA).
2.7. Quantitative Protein Analysis. Quantitative analysis of
the selected proteins in the culture media were performed
by speciﬁc ELISA following the manufacturer’s instructions
(GROα and ENA-78 were from R&D Systems, Minneapolis,4 Mediators of Inﬂammation
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Figure 1: Representative microscopic photographs (×100) of tumour cells exposed overnight to PMN. Tumour cells were cultured in 12-
well culture plates containing 12mm diameter cover glasses. 5 ×106 PMN were placed on culture inserts that were located over the wells
containing the tumour cells. Control, medium without PMN in the inserts; TW 3μm, PMN placed in 3μm pore size inserts; TW 0.4μm
fMLP, PMN activated with 0.1μmoles/L fMLP placed in 0.4μm pore size inserts; and TW 3μm Ab:CD18, CD162, CD44, PMN placed in
3μmporesizeinsertswith10μg/mLofmouseanti-humanCD44monoclonalantibody,10μg/mLofmouseanti-humanCD162monoclonal
antibodyand10μg/mLofmouseanti-humanCD18monoclonalantibody.CoverswerethenstainedwithAO-EB.AOpermeatesthroughout
the cells and renders the nuclei green. EB is taken up by the cells only when cytoplasmic membrane integrity is lost, and stains the nuclei red.
N = 3 with similar results.
MN;IL-8wasfromEndogen-Pierce,Rockford,IL;VEGFwas
from Biosource Europe, Fleurus, Begium).
2.8.FlowCytometryAnalysisofSurfaceICAM-1Expressionon
HMVEC. HT-29 and FaDu were cultured at conﬂuence as
aforementioned. The medium was then replaced, and after
48 hours, it was recovered and conditioning medium stored
at −80
◦C until used for HMVEC stimulation. Stimulation of
conﬂuent HMVEC was performed by replacing the medium
by DMEM containing 10% FBS (control), conditioning
medium from tumour cells or DMEM containing 10% FBS
and 10U/mL human recombinant IL-1β (positive control,
Roche Applied Science, Barcelona, Spain). After incubation
overnight, HMVEC were detached with Cell Dissociation
Solution (Sigma, St Louis, MO) centrifuged and suspended
in PBS pH 7.4 containing 2% of bovine serum albumin and
0.1% sodium azide. Twenty μL of commercial solution of
R-phycoerythrin (PE) labelled mouse anti-human ICAM-1Mediators of Inﬂammation 5
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Figure 2: Adhesion of PMN to tumour cells. 2 ×106 DiI-labeled
PMN were added to culture wells containing conﬂuent dermal
ﬁbroblasts (ﬁbroblasts), HMVEC (HMVEC), HT-29 (HT-29),
HT-29 with 10μg/mL of mouse anti-human CD44 monoclonal
antibody, 10μg/mL of mouse anti-human CD162 monoclonal
antibody and 10μg/mL of mouse anti-human CD18 monoclonal
antibody in the medium (HT-29 + AbCocktail), FaDu (FaDu),
FaDu with the Ab Cocktail (FaDu + AbCocktail), and HMVEC
previously treated with 10U/mL of human recombinant IL-1β for 5
hours (HMVEC + IL-1B) and incubated at 37
◦Cf o r3 0m i n u t e s .
After washing, adhered PMN were evaluated as described in the
Methods Section. Bars represent the mean ± SEM of 7 independent
experiments performed by sixtoplicate. Statistical signiﬁcance was
assessed using ANOVA test;
∗P <. 05,
∗∗P <. 01, and
∗∗∗P <. 001
when compared with HMVEC group.
(CD54, ref 555511, BD Pharmingen) were then added and
allowedtostandat4◦Cindarknessfor20minutes.Cellswere
then centrifuged, washed twice and suspended in 400μL PBS
containing 2% paraformaldehide. Flow cytometry analysis
was performed in a Cytomics FC500 cytometer (Beckman-
Coulter, Miami, FL).
3. Results
To observe the eﬀect of PMN on tumour cells, the tumour
cell lines were cultured in the bottom wells of transwell
devices; 5 ×106 PMN were added via the upper membrane
pores. The system was then left in a culture chamber
overnight. To determine the dependence of the cytotoxic
eﬀect of PMN on contact between the latter and tumour
cells, two kind of insert were used. In one set of experiments
PMN were placed on 3μm pore inserts which allow PMN
to pass through. These experiments were performed in the
absence and presence of a cocktail of antibodies against
CD18, CD162 and CD44 to prevent the ﬁrm adhesion
of the PMN to the tumour cells. In a second set of
experiments, PMN were placed on 0.4μm pore inserts to
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Figure 3: Tumour cell-induced PMN transmigration through
human microvascular endothelium. DiI-labeled PMN were added
to3μmporesizecellcultureinsertspreviouslycoatedwithHMVEC
cultured at conﬂuence. Inserts were placed upon culture wells
containing conﬂuent human dermal ﬁbroblast (ﬁbroblasts), HT-
29 (HT-29), FaDu (FaDu) and HMVEC previously treated with
10U/mL of human recombinant IL-1β for 5 hours (HMVEC + IL-
1B). See Methods. After 3 hours at 37
◦C, PMN in the lower side of
the system were evaluated as described in the Methods section. Bars
represent the mean±SEM of 7 independent experiments performed
by sixtoplicate. Statistical signiﬁcance was assessed using ANOVA
test;
∗P<. 05, and
∗∗∗P<. 001 when compared with ﬁbroblasts
group.
prevent their passage; these membranes, however, allow
mediator molecules to pass through. In these experiments,
the PMN were exogenously stimulated by adding fMLP to
the inserts. Control experiments consisted of placing culture
medium without PMN on the inserts.
A se x p e c t e d ,ac y t o t o x i ce ﬀect of PMN on the two
cultured cell lines was observed when PMN passed freely
through the upper inserts. A representative experiment is
shown in Figure 1. FaDu cells were more sensitive to PMN
than were HT-29 cells, whereas the complete destruction
of the cultured FaDu colonies was observed after overnight
incubation with PMN, 48 hours of incubation was necessary
for the complete destruction of HT-29 cultures (not shown).
When PMN were unable to pass through the membrane
(inserts pore diameter 0.4μm) no destruction of HT-29 cell
aggregates was observed even when PMN were stimulated
with fMLP; in addition, the cytotoxic eﬀect on FaDu was
clearly mitigated. Even when PMN crossed the membrane
(3μm diameter pore) a similarly reduced cytotoxic eﬀect was
observed when these PMN were in a cocktail of antibodies
directed against adhesion molecules (thus inhibiting the
adhesion of PMN to the tumour cells) (Figure 2). These
results indicate that direct contact and adhesion between
PMN and tumour cells is important, although not absolutely6 Mediators of Inﬂammation
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Figure 4: Protein array analysis of culture medium from HT-29, FaDu and human dermal ﬁbroblasts. Culture medium (DMEM plus 10%
FBS) was replaced and collected after 48 hours. Controls were performed with DMEM plus 10% FBS. The proteins that were analyzed are
indicated in the bottom panel; pos, positive controls, neg, negative controls. Bars are the densitometric evaluation of samples (right panel);
AU, arbitrary units. Values were calculated as the diﬀerence between the density value of samples and controls. Bars represent the mean of
two independent experiments. Doted lines indicate the value which comprise 75% of the proteins.Mediators of Inﬂammation 7
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Figure 5: Quantitative evaluation of the IL-8, growth related
oncogene-α (GROα), and vascular endothelial growth factor
(VEGF) released by HT-29 and FaDu in 48 hours. Culture medium
(DMEM plus 10% FBS) was replaced and collected after 48
hours. Protein levels were determined by ELISA. Bars represent the
mean ± SEM, n = 4. Statistical signiﬁcance was assessed using
Students t-test;
∗∗∗P <. 001 when compared with HT-29.
necessary in the case of FaDu, for these immune system cells
to exert their cytotoxic eﬀect.
To examine the ability of tumour cells to adhere to
PMN, 2 ×106 DiI-labelled PMN were directly added to
culture wells containing conﬂuent dermal ﬁbroblasts or
HMVEC (negative controls), tumour cells, tumour cells
with the cocktail of antibodies against adhesion molecules,
a n dH M V E Cp r e v i o u s l yt r e a t e dw i t h1 0 U / m Lo fh u m a n
recombinant IL-1β for 5 hours (positive control); all were
incubated at 37
◦C for 30 minutes. The results in Figure 2
show that PMN adhered to both HT-29 and FaDu cells. The
adhesion of PMN to tumour cells was signiﬁcantly greater
than their adhesion to dermal ﬁbroblasts and unstimulated
HMVEC. Treatment of PMN with the antibody-cocktail
against PMN adhesion molecules strongly reduced their
adhesion to tumour cells.
The ability of tumour cells to induce PMN transmi-
gration through a human microvascular monolayer was
examined by adding DiI-labelled PMN to 3μmp o r es i z e
cell culture inserts previously coated with HMVEC cultured
until conﬂuence. Inserts were placed on culture wells
containing conﬂuent human dermal ﬁbroblast (negative
control), tumour cell lines, and HMVEC previously treated
with 10U/mL of human recombinant IL-1β for 5 hours
(positivecontrol).Thetranswellsystemswerethenincubated
at 37
◦Cf o r3h o u r s .Figure 3 shows the number of PMN
that migrated toward the tumour cells in the bottom wells
over the 3 hours period. The number of PMN that crossed
the HMVEC layer was signiﬁcantly higher when the tumour
cells were in the bottom than when dermal ﬁbroblasts were
in this location. Tumour cells attracted PMN more so than
did HMVEC stimulated with IL-1β.
A nonquantitative protein expression array was used to
explore the cytokines and growth factors released by the
tumour cell lines. Human dermal ﬁbroblasts were included
in the analysis since these cells were used as negative controls
in many experiments. The results are shown in Figure 4.
Conditioning media from tumour cell cultures were positive
for many proteins. Densitometry evaluation of the array
spots was performed to estimate the relative expression of
the proteins evaluated (also shown in Figure 4). The major
chemokines released by both tumour cell lines were the
CXC-chemokines GROα and IL-8. Quantitative evaluation
of GROα, IL-8 and VEGF by ELISA showed that both HT-
29 and FaDu cells released substantial amounts of these
proteins, although levels in the FaDu conditioning medium
were an order of magnitude greater (Figure 5).
To determine the ability of tumour cells to activate
microvascular endothelium, HMVEC were subjected to
conditioning media from the tumour cell line cultures.
First, the proﬁle of cytokines and growth factors released
by HMVEC was determined using a protein array assay
(Figure 6). Culture medium from HMVEC stimulated with
IL-1β was clearly positive for MCP-1, IL-8, GROα and IL-6.
In addition, ENA-78, which was not released by the tumour
cells (see Figure 4), was speciﬁcally released by HMVEC. The
time course of the release of MCP-1, IL-8, ENA-78 and IL-6
by HMVEC exposed to IL-1β and conditioning media from
tumour cell lines is shown in Figure 7. IL-8 was the major
cytokine produced by the HMVEC. Conditioning medium
fromHT-29didnotstimulateHMVECtoreleaseanyprotein
forwhichtestsweremade.Incontrast,conditioningmedium
from FaDu cultures strongly induced HMVEC to release
the four cytokines. The production of MCP-1, IL-8 and
IL-6 induced by the FaDu conditioning medium was even
stronger than that induced by IL-1β.
To observe the eﬀect of tumour cell conditioning media
on the capacity of HMVEC to adhere to PMN, HMVEC
were exposed overnight to fresh culture medium (negative
control), conditioning media from tumour cells, or 10U/mL
of human recombinant IL-1β (positive control) before the
adhesion test was performed. After washing, 2 ×106 DiI-
labelledPMNwereaddedtotheHMVECandthenincubated
at 37
◦C for 30 minutes. Conditioning medium from tumour
cellssigniﬁcantly increased the adhesion of PMNto HMVEC
(Figure 8(a)). Once the value of the adhesion of PMN to
control HMVEC was subtracted, the FaDu conditioning
medium showed an almost 2-fold capacity to increase the
ability of HMVEC to adhere to PMN than did the HT-
29 conditioning medium. This was in agreement with the
induction of ICAM-1 (Figure 8(b)). The percentage of pos-
itive HMVEC cells (Figure 8(b), bottom left panel) treated
with FaDu conditioning medium or IL-1 (positive control)
was similar, whereas the percentage of positive HMVEC
treated with HT-29 conditioning medium was similar to that
obtained with the untreated controls. However, diﬀerences
in the percentage of positive HMVEC cells treated with
FaDu conditioning medium or IL-1β and the controls were
signiﬁcant (although not very important). This means that
many untreated HMVEC express ICAM-1 constitutively
(about 70% of the control cells and HT-29-treated HMVEC8 Mediators of Inﬂammation
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Figure 6: Protein array analysis of culture medium from HMVEC exposed to IL-1β. Culture medium was replaced by DMEM plus 10% FBS
and 10U/mL of human recombinant IL-1β, and collected after 48 hours. Controls were performed with DMEM plus 10% FBS and 10U/mL
of human recombinant IL-1β. The proteins that were analyzed are indicated in the bottom panel of Figure 4. Densitometric evaluation of
samples is also shown (right panel). Values were calculated as the diﬀerence between the density value of samples and controls. Columns
represent the mean of 2 independent experiments. The density value which comprise 75% of the proteins is indicated by the doted line. AU,
arbitrary units.
werepositive)andthatthenumberofcellsexpressingICAM-
1wasnotincreasedmuchbytreatmentwithFaDucondition-
ing medium or IL-1β (about 90% FaDu- and IL-1-treated
HMVEC were positive). Nevertheless, with respect to the
mean ﬂuorescence intensity, which is related to the density
of ICAM-1 (number ICAM-1 molecules/positive cell), the
treatment of HMVEC with FaDu or HT-29 conditioning
medium signiﬁcantly increased ICAM-1 expression in these
cells (although the FaDu conditioning medium was much
morepotentinthisrespect;Figure 8(b),rightbottompanel).
4. Discussion
The major aim of our study was to test the hypothesis that
tumour cells have proinﬂammatory properties and produce
cytokines and growth factors that condition the tumours for
attack by PMN. Our results are consistent with many reports
showing PMN cytotoxicity against tumour cells [3–9]. We
observed that the tumour cell lines that we used were sen-
sitive to PMN. When direct contact or adhesion of PMN to
tumour cells did not occur, cell lysis was drastically reduced
indicating that adhesion was an important condition for the
cytotoxic eﬀect of PMN on tumour cells. This is consistent
with data reported by others [27, 36].
We hypothesized that PMN action against tumours in
vivo requires that the tumour cells have the ability to act
as an inﬂammatory site. Obviously, the ﬁrst condition that
tumour cells must fulﬁl is to be able to attract PMN.
Both of the tumour cell lines (HT-29 and FaDu) that we
used accomplished this by secreting considerable amountsMediators of Inﬂammation 9
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Figure 7: Production of cytokines by HMVEC stimulated with tumour cell conditioning medium. HMVEC cultures were exposed to 48
hours-conditioning medium of HT-29 and FaDu for the indicated periods of time. Production of cytokines by HMVEC was calculated as
the diﬀerence between the value of samples and the initial amount in the conditioning mediums from tumour cells. Bars represent the mean
± SEM of 5 independent experiments performed by triplicate. Statistical signiﬁcance was assessed using multivariate Wilks statistic and one
sided Dunnet test to compare every treatment groups with the control group;
∗P<. 05,
∗∗P<. 01 and
∗∗∗P<. 001.
of CXC chemokines such as IL-8, and GROα. These results
are consistent with the ﬁnding that many tumour cell lines
constitutively produce IL-8 and other chemokines [47, 48].
It is noteworthy that the major chemokines produced by
theseHT-29andFaDu(IL-8andGROα)actmainlyonPMN
[49–51]. Constitutive production of chemokines by tumour
cells may be related to the constitutive activation of NF-κB
foundonmanytumourtypes[52,53].TheproductionofIL-
8bytumourcellshasbeeninterpretedusuallyastumorigenic
due to its pro-angiogenic and pro-metastatic properties [54–
57]. Nevertheless, the major biological activity of IL-8 is to
attract and activate leukocytes, particularly PMN [58–60]t o
the inﬂammation site and this activity could be potentially
antitumoral. The results from our transendothelial migra-
tion experiments indicated that the concentration of PMN
attractants in the conditioning media of both HT-29 and
FaDu was suﬃcient to recruit PMN eﬀectively.
Invivorecruitmentofleukocytesismediatedbyactivated
vascularendothelium[61].So,tumourcellsshouldbeableto
activate EC. We have shown that HT-29 and FaDu function-
ally induced adhesion of PMN to HMVEC. This correlated
with induction by the tumour cells of ICAM-1 expression
on the surface of HMVEC, which is an essential adhesion
molecule for surface attachment and transcellular migration
of PMN through vascular endothelium [62]. ICAM-1 is
the counter receptor for PMN β2-integrins [63]. These
integrins on the PMN surface are essential for adhesion and
PMN-mediatedcytotoxicity[64,65].Regardingactivationof
HMVEC to secrete chemokines, we observed a great diﬀer-
ence between HT-29 and FaDu. The former did not induced10 Mediators of Inﬂammation
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Figure 8: (a) Adhesion of PMN to HMVEC exposed to tumour cell conditioning medium. 2 ×106 DiI-labeled PMN were added to the
culture wells containing conﬂuent HMVEC previously treated overnight with none (control), HT-29 (HT-29) and FaDu (FaDu) 48 hours
conditioning medium, and 10U/mL of human recombinant IL-1β (IL-1B) and then incubated at 37
◦C for 30 minutes. After washing,
adhered PMN were evaluated as described in the Methods section. Bars represent the mean±SEM of 7 independent experiments performed
in sixtoplicate. (b) Surface expression of ICAM-1 in HMVEC exposed to tumour cell conditioning media. HMVEC previously treated
overnight with none (control), HT-29 (HT-29) and FaDu (FaDu) 48 hours conditioning medium, and 10U/mL of human recombinant IL-
1β (IL-1B) were detached and analyzed for ICAM-1 expression by ﬂow cytometry (see Methods). Upper panels represent histograms (out of
4) showing the eﬀect of tumour cell conditioning medium on ICAM-1 expression. Bottom panels show quantitative data. Bars represent the
mean ± SEM of 4 independent experiments. Statistical signiﬁcance was assessed using ANOVA test;
∗P <. 05,
∗∗P <. 01, and
∗∗∗P <. 001
when compared to control group.
signiﬁcant production of cytokines by the HMVEC, whereas
the later dramatically induced production of chemokines
and IL-6 by HMVEC. Moreover, the expression of MCP-
1, IL-8 and IL-6 was much higher in response to FaDu
conditioning medium than after treatment of HMVEC with
IL-1β.Theseresultsstronglysuggestthattherearediﬀerences
between diﬀerent tumours regarding their ability to promote
an inﬂammatory response. The nature of these diﬀerences
might explain the eﬃcacy of some tumours to act as sites of
inﬂammation. Also, such knowledge would help to design a
PMN-based anticancer therapy.
It is widely accepted that the elimination of any cancer
is possible by activating the host immune response [66]—
but this has not yet been translated into clinical practice.
Despite the increasing evidence demonstrating that innate
immunity, mainly associated with PMN, has an impressive
antitumoural capacity [26, 39–41, 67, 68], current immuno-
therapeutic developments in the ﬁeld of cancer are largely
based upon the stimulation of adaptive immunity [66,
69]. Adaptive mechanisms usually play a primary role in
initiating tissue-speciﬁc reactions that recruit innate eﬀector
cells, such as PMN, to the target organ, but these latter
cells are primarily responsible for tumour rejection [70].
The eﬀerent arm of the immune system, mainly PMN,
requires activation by appropriate signals at the tumour site
to undertake its functions. Established cancers usually either
do not send out such signals or send out signals insuﬃciently
potent to initiate and sustain a powerful inﬂammatory
response, and thus induce their own rejection. Evidence is
growing that the elimination of tumours using immunolog-
ical “weapons” is only possible by signiﬁcantly enhancing an
acute inﬂammatory response. There is probably a thresholdMediators of Inﬂammation 11
number of PMN required for their antitumour activity to be
eﬀective, and a simple way of achieving this is to increase
their circulating levels, as described by Br´ u et al. [37–40].
The present work was performed with only two estab-
lished tumour cell lines, but the results open up interesting
possibilities. If malignant tumours share the ability to
activate the natural mechanisms of local PMN recruitment,
it might be possible to produce an acute local inﬂammatory
response at tumour sites. PMN-based anticancer therapy
may be appropriate for tumours that that do not induce
as u ﬃciently strong immune response on their own. Very
recently, we reviewed the literature showing evidence that
many solid tumours can be destroyed by PMN in vitro
and/or in vivo [71].
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